0.645
0.00 (0.23%)
| Previous Close | 0.644 |
| Open | 0.669 |
| Volume | 27,925 |
| Avg. Volume (3M) | 55,939 |
| Market Cap | 15,117,058 |
| Price / Sales | 1.36 |
| Price / Book | 2.55 |
| 52 Weeks Range | |
| Earnings Date | 7 Aug 2023 - 11 Aug 2023 |
| Profit Margin | -15.45% |
| Operating Margin (TTM) | -17.43% |
| Diluted EPS (TTM) | -2.06 |
| Quarterly Revenue Growth (YOY) | 43.60% |
| Total Debt/Equity (MRQ) | 19.09% |
| Current Ratio (MRQ) | 0.760 |
| Operating Cash Flow (TTM) | 1.06 M |
| Levered Free Cash Flow (TTM) | 1.76 M |
| Return on Assets (TTM) | -10.90% |
| Return on Equity (TTM) | -25.29% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Mixed |
| Diagnostics & Research (Global) | Bullish | Mixed | |
| Stock | Precipio, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.50 |
|
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Core |
| % Held by Insiders | 14.13% |
| % Held by Institutions | 7.46% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 14 Nov 2025 | Announcement | Precipio Announces its Q3-2025 Financial Results |
| 04 Nov 2025 | Announcement | Precipio Announces Q3-2025 Shareholder Update Call |
| 02 Sep 2025 | Announcement | Precipio Terminates Its ATM |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |